Schering-Plough has received approval from the European Commission for its planned acquisition of Organon BioSciences from Akzo Nobel, creating the largest animal health company in the world.
Organon BioSciences is comprised mainly of Organon, the human pharmaceutical business, and Intervet, the animal health business. It also includes Nobilon, the human vaccine development unit, and Diosynth, the third-party manufacturing unit of Organon.
Animal health products
In connection with the approval, Schering-Plough has agreed to divest certain animal health products in Europe. The divestitures are not material to the company’s financial results. No divestitures of human health products are required.
The transaction, as announced on March 12, in which Schering-Plough would acquire Organon for €11 billion ($14.4 billion), still needs to secure certain regulatory approvals, including clearance from the US Federal Trade Commission (FTC), which is expected to be completed by year-end 2007.
Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. With 35,000 employees the combined animal health organization would have sales totalling $2.318 billion, based on 2006 sales.
â€¢ Schering Plough
â€¢ Federal Trade Commission
For the latest pig news, subscribe here